PNLIP and obesity disorder: Orlistat, a gastro–pancreatic lipase inhibitory agent, is now licenced for the treatment of long-term obesity, although it produces gastrointestinal adverse effects such as oily spotting, bloating, faecal urgency, faecal incontinence, and steatorrhoea [19].